168 related articles for article (PubMed ID: 33439689)
21. Melphalan kinetics in hyperthermic isolation perfusion of the extremities.
Loos U; Musch E; Rauschecker H; Willenbrock C
J Chemother; 1989 Jul; 1(4 Suppl):1246-7. PubMed ID: 16312851
[No Abstract] [Full Text] [Related]
22. [Gynecomastia appearing during myeloma: role of melphalan?].
Cohen JD; Fulpin J; Chouc PY; Jeandel P
Presse Med; 2000 Nov; 29(35):1936. PubMed ID: 11244624
[No Abstract] [Full Text] [Related]
23. Pepaxto: A New Peptide-Drug Conjugate for Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Jessee JK
Ann Pharmacother; 2022 Aug; 56(8):951-957. PubMed ID: 34963319
[TBL] [Abstract][Full Text] [Related]
24. Melphalan flufenamide for relapsed/refractory multiple myeloma.
Nadeem O; Mateos MV; Efebera YA; Paner A; Larocca A; Rodríguez-Otero P; Leleu X; Richardson PG
Drugs Today (Barc); 2022 Aug; 58(8):407-423. PubMed ID: 35983927
[TBL] [Abstract][Full Text] [Related]
25. Further progress in the treatment of multiple myeloma?
Malik PS; Kumar L
Natl Med J India; 2009; 22(1):25-7. PubMed ID: 19761157
[No Abstract] [Full Text] [Related]
26. A rapid intracellular enrichment of alkylating payload is essential for melphalan flufenamide potency and mechanism of action.
Westermark U; Diao Y; Fasth KJ; Färnegårdh M; Färnegårdh K; Hammer K; Lehmann F; Acs K; Svensson Gelius S
Biochem Biophys Res Commun; 2023 May; 656():122-130. PubMed ID: 37032581
[TBL] [Abstract][Full Text] [Related]
27. Melflufen for multiple myeloma: a promise unfulfilled?
Kapoor P; Gonsalves WI
Lancet Haematol; 2022 Feb; 9(2):e82-e84. PubMed ID: 35032433
[No Abstract] [Full Text] [Related]
28. Melflufen in multiple myeloma: the conclusion matters.
Hadidi SA
Lancet Haematol; 2022 Apr; 9(4):e244. PubMed ID: 35358437
[No Abstract] [Full Text] [Related]
29. Melflufen, a peptide-conjugated alkylator, is an efficient anti-neo-plastic drug in breast cancer cell lines.
Schepsky A; Traustadottir GA; Joelsson JP; Ingthorsson S; Kricker J; Bergthorsson JT; Asbjarnarson A; Gudjonsson T; Nupponen N; Slipicevic A; Lehmann F; Gudjonsson T
Cancer Med; 2020 Sep; 9(18):6726-6738. PubMed ID: 32717133
[TBL] [Abstract][Full Text] [Related]
30. Melflufen in multiple myeloma: the conclusion matters - Authors' reply.
Schjesvold FH; Bakker NA; Sonneveld P
Lancet Haematol; 2022 Apr; 9(4):e244-e245. PubMed ID: 35358436
[No Abstract] [Full Text] [Related]
31. In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia.
Strese S; Hassan SB; Velander E; Haglund C; Höglund M; Larsson R; Gullbo J
Oncotarget; 2017 Jan; 8(4):6341-6352. PubMed ID: 27974676
[TBL] [Abstract][Full Text] [Related]
32. Melphalan and its role in the management of patients with multiple myeloma.
Falco P; Bringhen S; Avonto I; Gay F; Morabito F; Boccadoro M; Palumbo A
Expert Rev Anticancer Ther; 2007 Jul; 7(7):945-57. PubMed ID: 17627453
[TBL] [Abstract][Full Text] [Related]
33. Proteometabolomics of Melphalan Resistance in Multiple Myeloma.
Koomen DC; Guingab-Cagmat JD; Oliveira PS; Fang B; Liu M; Welsh EA; Meads MB; Nguyen T; Meke L; Eschrich SA; Shain KH; Garrett TJ; Koomen JM
Methods Mol Biol; 2019; 1996():273-296. PubMed ID: 31127562
[TBL] [Abstract][Full Text] [Related]
34. The novel alkylating prodrug melflufen (J1) inhibits angiogenesis in vitro and in vivo.
Strese S; Wickström M; Fuchs PF; Fryknäs M; Gerwins P; Dale T; Larsson R; Gullbo J
Biochem Pharmacol; 2013 Oct; 86(7):888-95. PubMed ID: 23933387
[TBL] [Abstract][Full Text] [Related]
35. Peripheral blood progenitor cell collections in multiple myeloma: predictors and management of inadequate collections.
Prince HM; Imrie K; Sutherland DR; Keating A; Meharchand J; Crump RM; Girouard C; Trip K; Stewart AK
Br J Haematol; 1996 Apr; 93(1):142-5. PubMed ID: 8611448
[TBL] [Abstract][Full Text] [Related]
36. Proliferative activity, response to therapy and survival in multiple myeloma.
Riccardi A; Montecucco C; Merlini G; Ucci G; Cremonini N; Gobbi PG; Ascari E
Haematologica; 1984; 69(2):148-62. PubMed ID: 6429002
[No Abstract] [Full Text] [Related]
37. Advances in the treatment of hematological malignancies: current treatment approaches in multiple myeloma.
Ludwig H; Strasser-Weippl K; Schreder M; Zojer N
Ann Oncol; 2007 Jul; 18 Suppl 9():ix64-70. PubMed ID: 17631598
[No Abstract] [Full Text] [Related]
38. Comparison of two melphalan protocols and evaluation of outcome and prognostic factors in multiple myeloma in dogs.
Fernández R; Chon E
J Vet Intern Med; 2018 May; 32(3):1060-1069. PubMed ID: 29566439
[TBL] [Abstract][Full Text] [Related]
39. Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma.
Moreau P; Fiere D; Bezwoda WR; Facon T; Attal M; Laporte JP; Colombat P; Haak HL; Monconduit M; Lockhorst H; Girault D; Harousseau JL
J Clin Oncol; 1997 Feb; 15(2):660-6. PubMed ID: 9053491
[TBL] [Abstract][Full Text] [Related]
40. Stem cell mobilization in heavily pretreated multiple myeloma patients with prior high dose melphalan and auto-SCT.
Khaled Y; Al-Hazzouri A; Mizrachi A; Reynolds R; Reddy V; Solh M
Bone Marrow Transplant; 2013 Feb; 48(2):310-1. PubMed ID: 22773127
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
